KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2016 - 2018)

Emergent BioSolutions' Gains from Sales and Divestitures history spans 8 years, with the latest figure at $427610.0 for Q4 2018.

  • For Q4 2018, Gains from Sales and Divestitures rose 0.89% year-over-year to $427610.0; the TTM value through Dec 2018 reached $427610.0, up 0.89%, while the annual FY2018 figure was $427610.0, 0.89% up from the prior year.
  • Gains from Sales and Divestitures reached $427610.0 in Q4 2018 per EBS's latest filing, up from $423840.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $427610.0 in Q4 2018 to a low of $298489.0 in Q1 2014.
  • Average Gains from Sales and Divestitures over 5 years is $384188.2, with a median of $403992.0 recorded in 2017.
  • Peak YoY movement for Gains from Sales and Divestitures: rose 19.5% in 2015, then dropped 1.0% in 2016.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $361010.0 in 2014, then grew by 17.04% to $422515.0 in 2015, then decreased by 0.45% to $420599.0 in 2016, then rose by 0.77% to $423840.0 in 2017, then increased by 0.89% to $427610.0 in 2018.
  • Per Business Quant, the three most recent readings for EBS's Gains from Sales and Divestitures are $427610.0 (Q4 2018), $423840.0 (Q4 2017), and $413752.0 (Q3 2017).